CDEX Files Apparatus Patent Application for Portable, Hand-held Methamphetamine and Illicit Drug Detector; Company Prepares to Enter Homeland Security Market.

ROCKVILLE, Md. -- CDEX, Inc. (OTCBB:CEXI) announced today that it has filed an apparatus patent application for its Portable, Hand-held methamphetamine and Illicit Drug Detector in preparation for its entry into the Homeland Security market. The apparatus is capable of detecting trace amounts of methamphetamine, other illicit drugs, and other chemical substances. The apparatus incorporates CDEX core technology and will provide first responders (i.e., law enforcement, fire fighters, and HAZMAT teams) with a cost effective, real time method of conducting non-contact, non-destructive, field tests of suspicious substances.

Detection is accomplished by scanning a spectral beam across a surface to detect the presence of trace amounts of contamination left behind by methamphetamine, other illicit drugs, or other chemical substances. The device has the look and feel of a traffic radar gun, is battery operated, is capable of wired or wireless up/down loading of data, time and date stamps of all tests, and stores all test results for later retrieval.

"The development, protection, and practice of our intellectual property are vital to value creation for the company," said Jim Griffin, President and CEO of CDEX. "The innovative application of our intellectual property to life-safety products such as the Portable, Hand-held Methamphetamine and Illicit Drug Detector Illicit is a key success factor in meeting market demand and executing our growth strategy."

CDEX core technology is highly scalable. The company is currently developing products that incorporate the same patent pending technology currently used in existing CDEX products for other market segments. All current CDEX products are based on applying the same underlying photoelectric technology for which the company has five additional patents pending. CDEX has also filed corresponding international applications for each of these patents.

About CDEX, Inc.

CDEX Inc. is a technology development company with a current focus on developing and marketing products using chemical detection and validation technologies. At present, CDEX is devoting its resources to two distinct areas: (i) and quality assurance (e.g., validation of prescription medication and detection of counterfeit or sub-par products for brand protection). ValiMed is one line of CDEX products for the healthcare market; and (ii) identification of substances of concern (e.g., illegal drugs for law enforcement in the homeland security market) CDEX is headquartered in Rockville, Maryland with its research and development laboratory in Tucson, Arizona. For more information, visit www.cdex-inc.com.

Any statements made in this press release which contain information that is not historical are essentially forward-looking. Many forward-looking statements can be identified by the use of words such as "expects," "plans," "may," "anticipates," "believes," "should," "intends," "estimates," and other words of similar meaning. These statements are subject to risks and uncertainties that cannot be predicted or quantified and, consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks are detailed from time-to-time in filings with the Securities and Exchange Commission. There is no obligation to publicly update any forward-looking statements.